-
| Exchange | NASDAQ |
|---|---|
| CurrencyCode | USD |
| ISIN | US45828J1034 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | 22M |
|---|---|
| Beta | 4.22 |
| PE Ratio | None |
| Target Price | 2.9 |
| Dividend Yield | None |
Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for INTS using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2026